)
Visual
test
Nanobiotix
Nanobiotix (NANO) investor relations material
Nanobiotix Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary24 Nov, 2025
Executive summary
Closed a non-dilutive royalty financing with HealthCare Royalty (HCRx) valued up to $71 million, with $50 million upfront and $21 million expected in one year upon meeting conditions.
Advanced the JNJ-1900 (NBTXR3) global development program, including first Phase 1 data in esophageal cancer and transfer of Phase 3 study sponsorship to Johnson & Johnson in most regions.
Progressed the Curadigm Nanoprimer program with new patent filings, pre-clinical data, and external collaborations.
Financial highlights
€20.4 million in cash and cash equivalents as of September 30, 2025.
$50 million upfront payment from HCRx extends cash runway, with an additional $21 million expected, providing cash visibility into early 2028.
Outlook and guidance
Clinical updates expected in 2026 from ongoing or completed JNJ-1900 (NBTXR3) Phase 1 studies in melanoma, lung cancer, pancreatic cancer, and esophageal cancer.
Final and updated data from multiple studies, including those sponsored by MD Anderson, anticipated in 2026.
Detail HCRX repayment structure and EIB role
How does JNJ-1900 MoA support broad applicability?
Outline Curadigm's internal and external strategy
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nanobiotix
- NBTXR3 demonstrates strong efficacy and safety in head and neck cancer, warranting further trials.NANO
Status Update3 Feb 2026 - NBTXR3 plus radiation and anti-PD-1 achieved strong efficacy and safety in R/M HNSCC.NANOStudy Update31 Jan 2026
- Strong clinical progress and J&J partnership drive NBTXR3's path to market and new innovations.NANOH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- NBTXR3 shows strong promise in head and neck cancer, with pivotal Phase III data due in H1 2026.NANOGuggenheim Inaugural Global Healthcare Innovation Conference15 Jan 2026
- R3's phase III progress and $2.5B J&J deal highlight broad oncology potential.NANOStifel 2024 Healthcare Conference13 Jan 2026
- NBTXR3's phase III progress and J&J partnership drive major oncology and platform expansion.NANOJefferies London Healthcare Conference 202413 Jan 2026
- Curadigm's Nanoprimer boosts drug delivery by overcoming liver clearance, enabling broader therapeutic impact.NANOStatus Update10 Jan 2026
- NBTXR3 plus radiotherapy improved survival and biomarker response in pancreatic cancer.NANOStatus Update27 Dec 2025
- Clinical progress and financial discipline extend cash runway to mid-2026.NANOQ4 202426 Dec 2025
- J&J assumes pivotal trial costs, extending cash runway and supporting major clinical milestones ahead.NANOStatus Update26 Dec 2025
Next Nanobiotix earnings date
H2 20251 Apr, 2026
Nanobiotix
Next Nanobiotix earnings date
H2 20251 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage